Brolucizumab is under clinical development by Novartis and currently in Phase III for Proliferative Diabetic Retinopathy (PDR). According to GlobalData, Phase III drugs for Proliferative Diabetic Retinopathy (PDR) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Brolucizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brolucizumab overview

Brolucizumab-dbll (Beovu, Vsiqq, Vizcu, Pagenax) is a recombinant human vascular endothelial growth factor. It is formulated as solution for intravitreal route of administration. Beovu is indicated for the treatment of neovascular (Wet) age-related macular degeneration. Beovu is indicated for the treatment of diabetic macular edema.

Brolucizumab (DLX-1008) is under development for proliferative diabetic retinopathy. It is administered topically and intravitreally. The therapeutic candidate targets VEGF-A and is developed based on the Pentra technology platform which utilizes Pentra antibody fragments. It was also under development for the treatment of keloids, rosacea, Kaposi's sarcoma, diabetic macular edema and glioblastoma.

It was under development for the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion, macular edema secondary to central retinal vein occlusion.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

For a complete picture of Brolucizumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.